Cargando…

HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome

BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengtsson, Erik, Nerjovaj, Pashtrik, Wangefjord, Sakarias, Nodin, Björn, Eberhard, Jakob, Uhlén, Mathias, Borgquist, Signe, Jirström, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000148/
https://www.ncbi.nlm.nih.gov/pubmed/24708688
http://dx.doi.org/10.1186/1746-1596-9-78
_version_ 1782313585733533696
author Bengtsson, Erik
Nerjovaj, Pashtrik
Wangefjord, Sakarias
Nodin, Björn
Eberhard, Jakob
Uhlén, Mathias
Borgquist, Signe
Jirström, Karin
author_facet Bengtsson, Erik
Nerjovaj, Pashtrik
Wangefjord, Sakarias
Nodin, Björn
Eberhard, Jakob
Uhlén, Mathias
Borgquist, Signe
Jirström, Karin
author_sort Bengtsson, Erik
collection PubMed
description BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was examined. FINDINGS: Immunohistochemical expression of HMGCR was assessed in tissue microarrays with primary tumours from 557 incident cases of colorectal cancer in the Malmö Diet and Cancer Study. Pearson’s Chi Square test was applied to explore the associations between HMGCR expression and clinicopathological factors and other investigative biomarkers. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the relationship between HMGCR expression and cancer-specific survival (CSS) according to negative vs positive HMGCR expression. A total number of 535 (96.0%) tumours were suitable for analysis, of which 61 (11.4%) were HMGCR negative. Positive cytoplasmic HMGCR expression was associated with distant metastasis-free disease at diagnosis (p = 0.002), lack of vascular invasion (p = 0.043), microsatellite-instability (p = 0.033), expression of cyclin D1 (p = <0.001) and p21 (p = <0.001). Positive HMGCR expression was significantly associated with a prolonged CSS in unadjusted Cox regression analysis in the entire cohort (HR = 1.79; 95% CI 1.20-2.66) and in Stage III-IV disease (HR = 1.71; 95% CI 1.09-2.68), but not after adjustment for established clinicopathological parameters. CONCLUSIONS: Findings from this prospective cohort study demonstrate that HMGCR is differentially expressed in colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged survival in unadjusted analysis. The utility of HMGCR as a predictor of response to neoadjuvant or adjuvant statin treatment in colorectal cancer merits further study. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2115647072103464.
format Online
Article
Text
id pubmed-4000148
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40001482014-04-26 HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome Bengtsson, Erik Nerjovaj, Pashtrik Wangefjord, Sakarias Nodin, Björn Eberhard, Jakob Uhlén, Mathias Borgquist, Signe Jirström, Karin Diagn Pathol Short Report BACKGROUND: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological correlates and prognostic value of HMGCR expression in colorectal cancer was examined. FINDINGS: Immunohistochemical expression of HMGCR was assessed in tissue microarrays with primary tumours from 557 incident cases of colorectal cancer in the Malmö Diet and Cancer Study. Pearson’s Chi Square test was applied to explore the associations between HMGCR expression and clinicopathological factors and other investigative biomarkers. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the relationship between HMGCR expression and cancer-specific survival (CSS) according to negative vs positive HMGCR expression. A total number of 535 (96.0%) tumours were suitable for analysis, of which 61 (11.4%) were HMGCR negative. Positive cytoplasmic HMGCR expression was associated with distant metastasis-free disease at diagnosis (p = 0.002), lack of vascular invasion (p = 0.043), microsatellite-instability (p = 0.033), expression of cyclin D1 (p = <0.001) and p21 (p = <0.001). Positive HMGCR expression was significantly associated with a prolonged CSS in unadjusted Cox regression analysis in the entire cohort (HR = 1.79; 95% CI 1.20-2.66) and in Stage III-IV disease (HR = 1.71; 95% CI 1.09-2.68), but not after adjustment for established clinicopathological parameters. CONCLUSIONS: Findings from this prospective cohort study demonstrate that HMGCR is differentially expressed in colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged survival in unadjusted analysis. The utility of HMGCR as a predictor of response to neoadjuvant or adjuvant statin treatment in colorectal cancer merits further study. VIRTUAL SLIDES: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2115647072103464. BioMed Central 2014-04-07 /pmc/articles/PMC4000148/ /pubmed/24708688 http://dx.doi.org/10.1186/1746-1596-9-78 Text en Copyright © 2014 Bengtsson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Short Report
Bengtsson, Erik
Nerjovaj, Pashtrik
Wangefjord, Sakarias
Nodin, Björn
Eberhard, Jakob
Uhlén, Mathias
Borgquist, Signe
Jirström, Karin
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title_full HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title_fullStr HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title_full_unstemmed HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title_short HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
title_sort hmg-coa reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000148/
https://www.ncbi.nlm.nih.gov/pubmed/24708688
http://dx.doi.org/10.1186/1746-1596-9-78
work_keys_str_mv AT bengtssonerik hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT nerjovajpashtrik hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT wangefjordsakarias hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT nodinbjorn hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT eberhardjakob hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT uhlenmathias hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT borgquistsigne hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome
AT jirstromkarin hmgcoareductaseexpressioninprimarycolorectalcancercorrelateswithfavourableclinicopathologicalcharacteristicsandanimprovedclinicaloutcome